CVE-2026-24217
Nvidia Bionemo Framework path traversal
- Published20 May 2026
Description
NVIDIA BioNeMo Core for Linux contains a vulnerability where a user could cause a path traversal by loading a malicious file. A successful exploit of this vulnerability might lead to code execution, denial of service, information disclosure, and data tampering.
CVSS 3.1 breakdown
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:HAffected products
Remediation
References
Related CVEs
Recent high-severity vulnerabilities sharing a weakness type.
Frequently asked
Is CVE-2026-24217 being actively exploited?
CVE-2026-24217 is not in the CISA KEV catalog. Its EPSS exploit probability is 0.76%.
How severe is CVE-2026-24217?
CVE-2026-24217 has a CVSS 3.1 base score of 8.8, rated high. EPSS estimates a 0.76% probability of exploitation.
Which products are affected by CVE-2026-24217?
Affected products include Nvidia Bionemo Framework.
How do I fix CVE-2026-24217?
Upgrade affected software to a fixed version, for example Nvidia Bionemo Framework 2026-04-03 or later, then confirm no affected versions remain in your inventory.
How Secuno handles this
Secuno correlates vulnerabilities like CVE-2026-24217 against the real software inventory on every managed device, as each hourly inventory arrives. Rather than a static severity, each match is scored in context: exploit availability, EPSS, the asset's exposure, and business criticality decide where it lands in the queue. If an affected version is present anywhere across your portfolio, it surfaces automatically with a prioritised remediation path.
Data from the NVD, CISA KEV catalog and FIRST EPSS. CVSS 3.1 base score shown where available.